Nazer L, Lopez-Olivo MA, Cuenca JA, Awad W, Brown AR, Abusara A, Sirimaturos M, Hicklen RS, Nates JL. All-cause mortality in cancer patients treated for sepsis in intensive care units: a systematic review and meta-analysis.
Support Care Cancer 2022;
30:10099-10109. [PMID:
36214879 PMCID:
PMC9549043 DOI:
10.1007/s00520-022-07392-w]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Accepted: 10/03/2022] [Indexed: 11/28/2022]
Abstract
Purpose
Sepsis is a common complication in patients with cancer, but studies evaluating the outcomes of critically ill cancer patients with sepsis on a global scale are limited. We aimed to summarize the existing evidence on mortality rates in this patient population.
Methods
Prospective and retrospective observational studies evaluating critically ill adult cancer patients with sepsis, severe sepsis, and/or septic shock were included. Studies published from January 2010 to September 2021 that reported at least one mortality outcome were retrieved from MEDLINE (Ovid), Embase (Ovid), and Cochrane databases. Study selection, bias assessment, and data collection were performed independently by two reviewers, and any discrepancies were resolved by a third reviewer. The risk of bias was assessed using the Newcastle–Ottawa scale. We calculated pooled intensive care unit (ICU), hospital, and 28/30-day mortality rates. The heterogeneity of the data was tested using the chi-square test, with a P value < 0.10 indicating significant heterogeneity.
Results
A total of 5464 citations were reviewed, of which 10 studies met the inclusion criteria; these studies included 6605 patients. All studies had a Newcastle–Ottawa scale score of 7 or higher. The mean patient age ranged from 51.4 to 64.9 years. The pooled ICU, hospital, and 28/30 day mortality rates were 48% (95% CI, 43– 53%; I2 = 80.6%), 62% (95% CI, 58–67%; I2 = 0%), and 50% (95% CI, 38– 62%; I2 = 98%), respectively. Substantial between-study heterogeneity was observed.
Conclusion
Critically ill cancer patients with sepsis had poor survival, with a hospital mortality rate of about two-thirds. The substantial observed heterogeneity among studies could be attributed to variability in the criteria used to define sepsis as well as variability in treatment, the severity of illness, and care across settings. Our results are a call to action to identify strategies that improve outcomes for cancer patients with sepsis.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00520-022-07392-w.
Collapse